Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/3/2009

significant problem with recurrence in CDI patients, Optimer believes that the medical community is placing greater emphasis on global cure, defined as a cure without a recurrence. The global cure rate of fidaxomicin versus vancomycin was 77.7% versus 67.1% (p=0.006) in Optimer's North American Phase 3 trial.
  • Optimer expects to complete enrollment of the second Phase 3 trial of fidaxomicin in 2009, and anticipates reporting top-line data in the first quarter of 2010. The Company continues to engage in partnering discussions regarding fidaxomicin to maximize its value.
  • Optimer recently entered into a number of transactions involving OBI, the Company's Taiwan subsidiary, to provide OBI with funding for the development of two of Optimer's early-stage, non-core programs, OPT-88 and OPT-822/821, and to allow Optimer to focus on its late-stage anti-infective programs, fidaxomicin and Pruvel. Pursuant to these transactions, Optimer assigned to OBI certain patent rights, information and know-how related to OPT-88, a preclinical product candidate for the treatment of osteoarthritis, and OPT-822/821, a carbohydrate-based cancer immunotherapy product candidate. Optimer is eligible to receive up to $10 million in milestone payments and single-digit royalties on net sales for any product developed and commercialized under the programs. To provide capital for OBI's development of OPT-88 and OPT-822/821, Optimer and a group of new investors purchased approximately $3.7 million and $2.5 million, respectively, in new OBI common shares. Also in connection with the transactions, Optimer sold forty percent of its pre-transaction OBI common shares to the new investors for proceeds of $2.1 million. Optimer maintains a sixty percent ownership interest in OBI following the completion of these transactions.

    • Recent Corporate Highlights

    • Three fidaxomicin-related abstracts from Optimer's North American Phase 3 study in patients w
      '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
    2. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
    3. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
    4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
    5. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
    6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
    7. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
    8. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
    9. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
    10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
    11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    Breaking Biology News(10 mins):Self-destructing bacteria improve renewable biofuel production 2Self-destructing bacteria improve renewable biofuel production 3Researchers demonstrate nanoscale X-ray imaging of bacterial cells 2$2.4 million stimulus fuels effort to regenerate injured spinal cords 2$2.4 million stimulus fuels effort to regenerate injured spinal cords 3$2.4 million stimulus fuels effort to regenerate injured spinal cords 4Ingenious Med Announces a New Coding 26 Compliance Tool MasterCoder 50543 1Ingenious Med Announces a New Coding 26 Compliance Tool MasterCoder 50543 2Ingenious Med Announces a New Coding 26 Compliance Tool MasterCoder 50543 3New Report Finds Obesity Epidemic Increases Mississippi Weighs in as Heaviest State 50539 1New Report Finds Obesity Epidemic Increases Mississippi Weighs in as Heaviest State 50539 2New Report Finds Obesity Epidemic Increases Mississippi Weighs in as Heaviest State 50539 3New Report Finds Obesity Epidemic Increases Mississippi Weighs in as Heaviest State 50539 4New Report Finds Obesity Epidemic Increases Mississippi Weighs in as Heaviest State 50539 5New Report Finds Obesity Epidemic Increases Mississippi Weighs in as Heaviest State 50539 6New Report Finds Obesity Epidemic Increases Mississippi Weighs in as Heaviest State 50539 7SIRIUS XMs Doctor Radio to Air July 4th Family Special 24 Hours About Our Kids 3A Why Kids Behave the Way They Do 50535 1SIRIUS XMs Doctor Radio to Air July 4th Family Special 24 Hours About Our Kids 3A Why Kids Behave the Way They Do 50535 2SIRIUS XMs Doctor Radio to Air July 4th Family Special 24 Hours About Our Kids 3A Why Kids Behave the Way They Do 50535 3SIRIUS XMs Doctor Radio to Air July 4th Family Special 24 Hours About Our Kids 3A Why Kids Behave the Way They Do 50535 4SIRIUS XMs Doctor Radio to Air July 4th Family Special 24 Hours About Our Kids 3A Why Kids Behave the Way They Do 50535 5SIRIUS XMs Doctor Radio to Air July 4th Family Special 24 Hours About Our Kids 3A Why Kids Behave the Way They Do 50535 6